Clinical Investigation| Volume 355, ISSUE 1, P48-53, January 2018

Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies

Published:August 22, 2017DOI:



      The aim of this study was to compare the heterogeneity of interstitial lung disease (ILD) in patients with polymyositis and dermatomyositis (PM/DM) according to serological type.


      A total of 182 patients with PM/DM-ILD were observed retrospectively. Antiaminoacyl-tRNA synthetase (ARS) and antimelanoma differentiation-associated gene5 (MDA5) antibodies were screened using immunoblotting approach. The patients with ILD were divided into 3 groups: MDA5 (with anti-MDA5 antibody), ARS (with anti-ARS antibody) and MSN (without anti-MDA5 or anti-ARS antibody) group. Pulmonary features, treatment responses and prognoses were compared among the groups.


      A higher percentage of rapidly progressive ILD (RP-ILD) occurrences (55.8% versus 25% versus 16.9%, P < 0.001) was observed in the MDA5 group compared to ARS and MSN groups. The MSN group experienced lower dyspnea (48.2% versus 79% versus 71.4%, P = 0.001) and fever (18.1% versus 39.5% versus 37.5%, P = 0.01) frequencies compared to MDA5 and ARS groups. Response to 6-month treatment among 95 patients showed highest deterioration ratio (70%, P = 0.001) of ILD in the MDA5 group. Additionally, the highest frequency of ILD improvement (60%, P = 0.04) was observed in the ARS group. During the observation period, 24 patients died of respiratory failure. The 5-year survival rates were significantly lower in MDA5 group (50.2%) compared to ARS group (97.7%) or the MSN group (91.4%) (P < 0.001).


      MDA5-ILD was associated with severe pulmonary manifestations, poor response to treatment and aggravated prognosis. The ARS-ILD group had favorable treatment response and prognosis. MSN-ILD patients had relatively worse treatment response and prognosis compared to the ARS group, even though they expressed milder pulmonary manifestation.

      Key Indexing Terms

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of the Medical Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Rider L.G.
        • Miller F.W.
        Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies.
        J Am Med Assoc. 2011; 305: 183-190
        • Kiely P.D.
        • Chua F.
        Interstitial lungdisease in inflammatory myopathies: clinical phenotypes and prognosis.
        Curr Rheumatol Rep. 2013; 15: 359
        • Mielnik P.
        • Wiesik-Szewczyk E.
        • Olesinska M.
        • et al.
        Clinical features and prognosis ofpatients with idiopathic inflammatory myopathies andanti-Jo-1 antibodies.
        Autoimmunity. 2006; 39: 243-247
        • Hoshino K.
        • Muro Y.
        • Sugiura K.
        • et al.
        Anti-MDA5 and anti-TIF1-{gamma} antibodies have clinical significance for patients with dermatomyositis.
        Rheumatology (Oxford). 2010; 49: 1726-1733
        • Solomon J.
        • Swigris J.
        • Brown K.K.
        Myositis-related interstitial lung disease and anti-synthetase syndrome.
        J Bras Pneumol. 2011; 37: 100-109
        • Hozumi H.
        • Enomoto N.
        • Kono M.
        • et al.
        Prognostic significance of anti-aminoacyltRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study.
        PLoS One. 2015; 10: e0120313
        • Gono T.
        • Kawaguchi Y.
        • Satoh T.
        • et al.
        Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis.
        Rheumatology (Oxford). 2010; 49: 1713-1719
        • Sato S.
        • Kuwana M.
        • Fujita T.
        • et al.
        Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease.
        Mod Rheumatol. 2013; 23: 496-502
        • Hozumi H.
        • Fujisawa T.
        • Nakashima R.
        • et al.
        Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
        Respir Med. 2016; 121: 91-99
        • Moghadam-Kia S.
        • Oddis C.V.
        • Sato S.
        • et al.
        Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis.
        Arthritis Care Res (Hoboken). 1668; 20: 689-694
        • Bohan A.
        • Peter J.B.
        Polymyositis and dermatomyositis (first of the two parts).
        N Engl J Med. 1975; 292: 344-347
        • Sontheimer R.D.
        Would a new name hasten the acceptanceofamyopathicdermatomyositis (dermatomyositis sine' myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?.
        J Am Acad Dermatol. 2002; 46: 626-636
        • Travis W.D.
        • Costabel U.
        • Hansell D.M.
        • et al.
        An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
        Am J Respir Crit Care Med. 2013; 188: 733-748
        • Koreeda Y.
        • Higashimoto I.
        • Yamamoto M.
        • et al.
        Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies.
        Intern Med. 2010; 49: 361-369
        • Nakashima R.
        • Hosono Y.
        • Mimori T.
        Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease.
        Lupus. 2016; 25: 925-933
        • Saketkoo L.A.
        • Ascherman D.P.
        • Cottin V.
        • et al.
        Interstitial lung disease in idiopathic inflammatory myopathy.
        Curr Rheumatol Rev. 2010; 6: 108-119
        • Kawasumi H.
        • Gono t
        • Kawaguchi Y.
        • et al.
        Recent treatment of interstitial lung disease with idiopathic inflammatory myopathies.
        Clin Med Insights Circ Respir Pulm Med. 2015; 9: 9-17
        • Merlo G.
        • Clapasson A.
        • Cozzani E.
        • et al.
        Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets.
        Arch Dermatol Res. 2017; 309: 87-95
        • Yoshida N.
        • Okamoto M.
        • Kaieda S.
        • et al.
        Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
        Respir Investig. 2017; 55: 24-32
        • Moghadam-Kia S.
        • Oddis C.V.
        • Sato S.
        • et al.
        Anti-MDA5 is associated with rapidly progressive lung disease and poor survival in U.S. patients with amyopathic and myopathic dermatomyositis.
        Arthritis Care Res (Hoboken). 2016; 68: 689-694
        • Gono T.
        • Kuwana M.
        Inflammatory myopathies: choosing the right biomarkers to predict ILD in myositis.
        Nat Rev Rheumatol. 2016; 12: 504-506
        • Guglielmi S.
        • Merz T.M.
        • Gugger M.
        • et al.
        Acute respiratory distress syndrome secondary to antisynthetase syndrome is reversible with tacrolimus.
        Eur Respir J. 2008; 31: 213-217
        • Tillie-Leblond I.
        • Wislez M.
        • Valeyre D.
        • et al.
        Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradualonset.
        Thorax. 2008; 63: 53-59
        • Hyldgaard C.
        • Bendstrup E.
        • Wells A.U.
        • et al.
        Unclassifiable interstitial lung diseases: clinical characteristics and survival.
        Respirology. 2017; 22: 494-500
        • Gono T.
        • Kawaguchi Y.
        • Hara M.
        • et al.
        Increased ferritin predicts development and severity of acute interstitial lung disease as complication of dermatomyositis.
        Rheumatology (Oxford). 2010; 49: 1354-1360
        • Tsuda T.
        • Asanuma Y.
        • Koyama S.
        • et al.
        A case of hypomyopathic dermatomyositis associated with rapid progressive interstitial pneumonia resistant to multi-immunosuppressive therapy.
        Am J Med Sci. 2007; 333: 185-190
        • Yokoyama T.
        • Sakamoto T.
        • Shida N.
        • et al.
        Fatal rapidly progressive interstitial pneumonitis associated with amyopathic dermatomyositis and CD8 T lymphocytes.
        J Interns Care Med. 2005; 20: 160-163